The CTSI provides pilot funding for innovative translational research and the development of innovative translational research methods at BU. This encompasses the continuum from the development of new therapies and diagnostic tests to studies of the population health impact of health interventions.
As all Pilot Translational and Clinical (PTC) pilot projects must have clear paths to translation and commercialization, the program includes entrepreneurs and business executives from relevant industries as reviewers and project advisers. For example, the Coulter Translational Partnership, the Ignition Award, and NIH NIBIB Center for Future Technologies in Cancer Care programs include on their grant review panels individuals with extensive industry and entrepreneurial leadership experience in pharmaceutical development, biotechnology, or biomedical engineering. One of the CTSI’s advisory committees that offer stakeholder perspective and advice, the Biotechnology Advisory Committee, generally focuses on risk–benefit analyses for pilot award funding for applications with a technology base.
REQUEST FOR APPLICATIONS INTEGRATED PILOT GRANT PROGRAM ANNOUNCEMENT – FALL 2017
Release Date: August 9, 2017
Pre-Application Deadline: September 15, 2017 at 5PM EST
Full-Application Deadline: October 18, 2017 at 5PM EST
Scientific Merit Review: November, 2017
Funding Decision Date: December, 2017
Earliest Start Date: January 1, 2018
PURPOSE OF THE CTSI PILOT GRANT PROGRAM
To stimulate individual and team science in all areas of translational research related to the prevention, diagnosis, and management of human disease. Researchers engaged in basic research, patient-oriented research, implementation science research, community engagement research, and population-based research are encouraged to apply. The CTSI welcomes applications that are at all levels of development including:
T1 research that develops novel treatments and interventions by expediting the movement between basic research and patient-oriented research leading to new or improved scientific understanding or standards of care.
T2 research that tests the efficacy and effectiveness of interventions through patient-oriented research and population-based research leading to better patient outcomes, the implementation of best practices, and improved health status in communities.
T3 research that promotes dissemination and implementation of research for system-wide change through movement of evidence based-guidelines into clinical practice.
T4 research that promotes discoveries in population science.
PURPOSE OF THIS SPECIFIC RFA
This specific RFA represents a collaborative effort between CTSI and partner organizations to fund meritorious research applicable to the components noted below. Applications must be responsive to one (or more) of the following:
- Community-Engaged Research
These projects must be designed to stimulate community-academic partnerships with the goals of catalyzing innovative translational research that is responsive to community health needs. We define our community as the diverse, vulnerable populations served by Boston Medical Center and our affiliated community health centers.
- BU School of Medicine (BUSM)
BU School of Medicine (BUSM) funds the following opportunities for BUSM faculty working in BUSM space to leverage grant submissions through the BU Office of Sponsored Programs with a preference for coordinated applications from multiple investigators (program projects) for research or infrastructure (lecture series, cell lines, core equipment).
- BUSM General Funds.
- The Shipley Prostate Cancer Program – Supports proposals with a preference for projects leading to more accurate diagnostics and precision medicine.
- Dahod Breast Cancer Center.
- The School of Medicine Breast Cancer Program – Proposals and Pilot Grants Eligibility is restricted to BUSM faculty who perform research activities in BUSM space, with the objective to develop follow-on grant submissions through the BU Office of Sponsored Programs. Applications from individual or teams of investigators studying breast cancer will be considered. Coordinated applications from multiple investigators (program projects) will be considered.
- The Wing Tat Lee Endowment – Supports collaborations between BUSM faculty and faculty at a mainland Chinese university (with preference for Hong Kong). The cooperative programs may include training faculty from either institution; holding seminars, workshops and symposia; and carrying out research projects of common interest.
- Boston University Cancer Center
The BU-BMC Cancer Center is looking to fund innovative and translational pilot projects focused in the following programmatic areas:
- Cancer Biology – Understanding the cellular and molecular underpinnings of carcinogenesis to develop more effective treatment and prevention strategies.
- Cancer Interception – Identification of the cellular and molecular events (induced by environmental exposures) associated with cancer initiation and progression that can be translated into novel tools for early detection and prevention of cancers.
- Population Sciences – Decrease cancer incidence and mortality through the identification of exposures and genetic factors that affect cancer risk and prognosis, as well as understanding the healthcare disparities that affect the patients seen at BMC.
- Cancer Bioengineering – Identifying and developing formulations for small molecules, technological platforms for diagnostics and therapeutic delivery systems for cancer.
- BU Henry M Goldman School of Dental Medicine (BUSDM)
This component specifically funds meritorious applications from BUSDM faculty.
- Boston Medical Center (BMC)
This component funds applications with research objectives consistent with the mission of Boston Medical Center (http://www.internal.bmc.org/about/mission.html). In specific, applications must be responsive to the following subject areas: (1) to define or innovate novel models of care, or (2) to discover effective ways to disseminate or implement existing evidence-based care models. Proposed projects should be relevant to the care of BMC’s patient population, and might include (but are not limited to) addiction services, prevention, chronic illness management, social determinants of health, or integrated behavioral health. Investigators should explain how their pilot proposals fit into the translational spectrum of research.
- Evans Center for Biomedical Research
This component represents a collaboration between the CTSI, the BU Interdisciplinary Biomedical Research Office (http://www.bu.edu/research/ibro), and the Evans Center for Interdisciplinary Biomedical Research (http://www.bumc.bu.edu/evanscenteribr). The objective is to (1) fund projects from non-ARC affiliated investigators that facilitate entry into an established Evans Center ARC, (2) fund projects from current ARC investigators that expand a current ARC with new an innovative direction, or (3) fund projects from any investigator that contribute to the development of a new ARC in the following year. Dual investigator applications are welcome, yet all application categories will be judged and selected for funding based on scientific merit.
- Applicants must have a primary, full-time faculty appointment at Boston University, and the research to be conducted must be based at Boston University, Boston Medical Center or any of their affiliated hospitals and health centers. Faculty with co-appointments at BU and affiliated institutions are also encouraged to apply.
- Community-engaged research: To qualify for funding in this category, a project must include at least one of the following methods: a) have a community stakeholder collaborator as a partner; b) The content of research should be responsive to some identified community health need, such as defined by the BMC Community Health Needs Assessment (http://www.bmc.org/Documents/BMC-Community-HealthNeedsAssessment-HNA.pdf) and/or c) methods should employ community-engaged research methods (http://www.atsdr.cdc.gov/communityengagement/) including but not limited to a dissemination plan that ensures findings are shared with the target community.
- Recipients of previous CTSI awards are eligible to apply for awards to support new research projects, providing awards are at least two years apart
- Applications from individuals of under-represented minorities are highly encouraged to apply
Direct costs up to $20,000 may be requested (with the exception of the BUSM-funded awards where up to $30,000 can be requested). The level of funding awarded to successful applicants will be determined after review of the budget request and budget justification. Funds may be used for any purpose to support the proposed research. Typical expenses include:
- Laboratory supplies
- Animal costs
- Small equipment
- Patient recruitment costs
- Support for pre/postdoctoral students, technicians, or research assistants.
Funds may not be allocated to PI or Co-I salary. Awards are not transferable to any other institution (sub-awards are not allowed). Department of Medicine awards must be spent by the end of the fiscal year in which they are awarded. Pilot grants are not intended to supplement existing NIH grants.
The BU CTSI is funded through a CTSA grant available from the NIH’s National Center for Advancing Translational Sciences (NCATS). Prior to the release of Pilot Grants funded directly with CTSI funds, NCATS requires the review and approval of all BU CTSI pilot grants involving research participants. If your proposal is funded and involves research participants, the CTSI will require additional documentation for NCATS. NCATS reviews take approximately 30 days.
Human Subject approval is not required at the time of submission; However, IRB approval is required for all projects involving human subject research before NCATS will approve project funding.
If your project involves animal research, IACUC and Office of Laboratory Animal Welfare (OLAW) must approve any projects involving animal subjects prior to final funding approval.
Evidence of prior or ongoing IRB & IACUC review is encouraged for all applications.
NEW THIS CYCLE AND GOING FORWARD:
The CTSI Integrated Pilot Grant Program has instituted a new application process that now consists of a 2-step process:
- Pre-Applications are now required
- Full-Applications will be based on invitation
PRE APPLICATION PROCESS - Step 1
- Pre-applications require a short abstract (Maximum of 1 page or less) along with NIH formatted biosketches for the PI and Co-PIs. Pre-applications are submitted by going here.
- Pre-applications are reviewed by a faculty committee comprised of the Full Review Panel Chairs and representatives of the BU CTSI Leadership Team
- The review committee makes recommendations as to whether or not an applicant will be invited to submit a full proposal. The objective is to (1) establish the feasibility of the proposed research in the 1-year timeframe of the award and (2) assure that regulatory steps required permitting research activities are complete in a timely manner.
- Applicants are notified via email if they are invited to submit a full proposal
- The process for submitting a full application is below
- To submit a pre-application you must first submit an NOI, go here to submit the NOI. Once the NOI is submitted you will receive an electronic notification which allows you to enter the electronic portal to start the pre-application process. You may access the application at any time after submitting your NOI by going here.
FULL APPLICATION PROCESS - Step 2
- The full-application must include:
- A maximum of three pages describing the background, specific aims, preliminary studies (if applicable), research methods (including timeline), commercial potential and future grant submissions or commercial development
- A budget & budget justification
- Other relevant supporting documentation (optional) may also be included if its relevant to the application
- You may access the application information submitted during the pre-application process at any time after submitting your NOI by going here.
- Full-Applications will be meritoriously reviewed by BU CTSI Scientific Review Committees (SRC) comprised of faculty with relevant expertise analogous to the NIH review process (with focus on Significance, Innovation, Approach, and Investigators). All applications will be reviewed and ranked for funding priority. Specific review criteria include, but are not limited to:
- Significance of the work in terms of potential health impact
- Scientific rigor and novelty of the proposed approach
- Likelihood that the project will lead to subsequent external funding and/or commercial development
- Multidisciplinary collaboration
- High potential for impact in the prevention, diagnosis, or treatment of human health conditions in broad terms. Projects closer to translation will be prioritized over more preliminary projects that are further from translation.
- Qualification of the research team
- Need for the funding
- Likelihood that the project can be completed within the budget period noted above
- Although not required that applicants be junior investigators, the review process will consider career development.
- Although not required, other features that may increase a project’s priority include:
- A clear translational focus, including a collaboration with a patient oriented science research team
- Focus on diseases disproportionately affecting the BU/BMC patient population
- Approved IRB or IACUC protocols that would permit initiation of research activities as soon as possible
RESOURCES TO ASSIST WITH YOUR PILOT GRANT APPLICATION
The CTSI offers an array of research resources in support of research at BU and we strongly encourage CTSI Pilot Grant applications to use these valuable resources. Some examples include the following:
- Regulatory Support
- Grant Writing & Editing, Formatting and Editing Services
- Biostatistics, Data Management & Analysis
- Research Tools
- Study Implementation
- Research Networking
For a complete list of available resources, please visit the CTSI website at http://www.bu.edu/ctsi/support-for-research/pilot-awards/.
- If funded, the awardee agrees to submit an online report after the end of the award term indicating key results and any publications, grant applications, funded awards that resulted from the project, new collaborations, and other outcomes. Additional abbreviated reports will be requested on an annual basis for 2 years following completion of funding. Any follow on funding depends on prompt and accurate progress reports. Awardees will be contacted regarding the report, once needed.
- Awardees must acknowledge the CTSI grant, the language provided below is recommended:
- “This publication [or project] was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Boston University Clinical & Translational Science Institute Grant Number 1UL1TR001430. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.”
- Awardees are expected to serve on future CTSI Pilot Grant Application Review panels and to provide feedback on the CTSI pilot program
- Awardees may be asked to participate in CTSI related symposia or other functions
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this RFA and welcome the opportunity to answer questions from potential applicants. Direct your questions to:
|Frederick L. Ruberg, MD
Section of Cardiovascular Medicine, Department of Medicine
Director, Pilot Grant Programs,
Boston University Clinical and Translational Science Institute
Boston University School of Medicine
Boston University Clinical and Translational Science Institute
Fall 2016 PILOT AWARDS:
In January, the CTSI announced the Fall 2016 pilot awards. The CTSI received 80 proposals from investigators across BU. A total of 39 investigators were awarded $360,000 in pilot awards funded by the BU-CTSI, Boston Medical Center; The BU School of Dental Medicine; The BU School of Medicine and the BU-BMC Cancer Center. Congratulations to all recipients!
|Devyani Misra||BUSM Medicine|
|Deepak Kumar||SAR Physical Therapy & Athletic Training|
|Sarah Valentine||BUSM Psychiatry|
|Julia Xu||BUSM Medicine|
|Robert Helm||BUSM Medicine|
|Barbara Nikolajczyk||BUSM Microbiology|
|Deborah Stearns-Kurosawa||BUSM Pathology & Laboratory Medicine|
|Elise Morgan||ENG Mechanical Engineering|
|Louis Awad||Sargent College|
|Irving Bigio||ENG Biomedical Engineering|
|Casey Taft||Psychiatry and Behavioral Sciences|
|Francesca Seta||BUSM Medicine|
|Ann Egloff||GSDM Molecular & Cell Biology|
|Stefano Monti||BUSM Medicine|
|Gerald Denis||BUSM Medicine|
|Philip Trackman||GSDM Molecular & Cell Biology|
|Rachel Flynn||BUSM Pharmacology & Experimental Therapeutics|
|John Porco||CAS Chemistry|
- Statistics from the recent spring 2017 CTSI-Integrated pilot program-To date we have received a total of 35 proposal and have 18 proposals under consideration deferred from the Fall 2016 funding cycle
- Summer 2017 information session